Acquisition Overview - AbbVie has completed the acquisition of Nimble Therapeutics, integrating it into its operations [1] - The acquisition includes Nimble's lead asset, an investigational oral peptide IL23R inhibitor for psoriasis, currently in preclinical development [2] - Nimble's proprietary peptide synthesis, screening, and optimization platform is now part of AbbVie's R&D capabilities [2] Strategic Benefits - The acquisition strengthens AbbVie's immunology pipeline by adding novel oral peptide assets [3] - AbbVie aims to integrate Nimble's proprietary technology to enhance its R&D capabilities [3] - The talented team from Nimble, known for their commitment to improving care for autoimmune diseases, has joined AbbVie [3] Company Background - AbbVie focuses on discovering and delivering innovative medicines across key therapeutic areas including immunology, oncology, neuroscience, and eye care [4] - The company also offers products and services under its Allergan Aesthetics portfolio [4]

Collaboration leverages AbbVie's expertise in oncology and immunology drug development and Neomorph's leading molecular glue discovery platform Neomorph to receive an upfront payment and is eligible to receive future option fees and milestones of up to $1.64B NORTH CHICAGO, Ill. and SAN DIEGO, Jan. 23, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Neomorph, Inc. today announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple targets across oncology and ...

Many products sold by companies aren't must-have items. However, healthcare is a necessity. And the healthcare sector is poised to grow over the next decade and beyond with aging populations around the world.These factors make healthcare stocks a great addition to investors' portfolios. You won't need a huge amount of cash to get started investing, either. If you have only $1,500 to invest, here are three healthcare stocks to buy and hold forever (listed alphabetically).1. AbbVieSooner or later, every succe ...

You've probably heard this before: Pharmaceutical stocks can bring an element of safety to your portfolio. Why is this the case? These companies make drugs doctors and patients rely on -- and that means no matter what the economy is doing, doctors will continue prescribing and patients will continue buying these treatments. All of this equals a rather steady stream of revenue for a pharma company, and this could translate into positive stock price performance over time.Sales of these drugs also have helped ...

Investors seeking a steadily growing passive income stream want to turn their heads toward the healthcare sector. Unlike with enterprise software sales or consumer goods, spending on healthcare tends to move in a positive direction regardless of what's happening to the overall economy.In 2023, the national health expenditure grew 7.5% to $4.9 trillion. With strong positions in the pharmaceutical and medical technology industries, AbbVie (ABBV -1.23%), Johnson & Johnson (JNJ -0.50%), and Medtronic (MDT 1.06% ...

Introduction If there's one thing we have been talking about almost nonstop, it's inflation. As you can imagine, this article won't be an exception. In general, inflation is an important topic, as it's a silent killer of our wealth. While ...

AbbVie (ABBV) closed the latest trading day at $173.70, indicating a +1.37% change from the previous session's end. This change outpaced the S&P 500's 0.21% loss on the day. Elsewhere, the Dow saw a downswing of 0.16%, while the tech-heavy Nasdaq depreciated by 0.89%.The drugmaker's shares have seen a decrease of 0.97% over the last month, surpassing the Medical sector's loss of 2.46% and the S&P 500's loss of 1.56%.The upcoming earnings release of AbbVie will be of great interest to investors. The company' ...

Key Points Company and Industry 1. **Company**: AbbVie Inc. (NYSE: ABBV) 2. **Event**: J.P. Morgan 43rd Annual Healthcare Conference 3. **Date**: January 15, 2025 4. **Time**: 11:15 AM ET 5. **Participants**: - Rob Michael - CEO - Scott Reents - Executive Vice President, CFO - Jeff Stewart - Executive Vice President, Chief Commercial Officer - Roopal Thakkar - Executive Vice President, Research & Development, Chief Scientific Officer - Chris Schott - J.P. Morgan [1] Core Views and Arguments 1. **CEO Rob Michael's Performance**: Rob Michael expresses satisfaction with the company's performance, noting that they are beating their top line by $1.8 billion and earnings are well ahead of expectations. 2. **Focus on Growth Platform**: Michael emphasizes the importance of executing the growth platform effectively, which he believes will provide a clear runway for growth for at least the next 8 years. 3. **Pipeline Expansion**: Michael also highlights the need to add to the pipeline to ensure sustained growth beyond the current period. [3][4] Other Important Points 1. **Investor Perception**: Michael acknowledges that investors may not fully appreciate the company's clear runway for growth over the next 8 years. 2. **Management Team**: The conference call features a broad swath of AbbVie's management team, indicating a collaborative approach to the company's strategy and execution. [3][4]

AbbVie’s (ABBV) stock has declined 8% in the past three months. A lot of this price decline is due to the poor performance of the overall drug and biotech sector in the past couple of months after Trump picked Robert F. Kennedy Jr., a vaccine skeptic, to be the next secretary of the Department of Health and Human Services, the agency that oversees the FDA.This, coupled with disappointing third-quarter sales and profits, guidance cuts and pipeline setbacks took a toll on the overall drug and biotech industry ...

Dividend growth investing is a powerful strategy for building lasting wealth. Companies that consistently raise their dividends tend to possess durable competitive advantages, robust cash flows, and shareholder-friendly management teams.These characteristics make dividend growth stocks compelling investments in any market environment. The strategy's success stems from the financial discipline and steady execution these companies demonstrate, making them ideal portfolio cornerstones for investors seeking bot ...